Why a pregnancy sickness drug is still hard to get on the NHS

Hyperemesis gravidarum can make it impossible to keep food or drink down, yet the treatment a woman gets can still depend on where she lives and which clinician sees her first. The NHS estimates the severe form of nausea and vomiting in pregnancy affects around 1 to 3 in every 100 pregnant women, though the true number is uncertain because some cases are never reported. When symptoms escalate, the condition can bring dehydration, weight loss, electrolyte imbalance and hospital treatment.

When morning sickness becomes HG

Hyperemesis gravidarum is not ordinary nausea. It is the point at which pregnancy sickness starts to threaten hydration, nutrition and day-to-day functioning, and some women need hospital care because they cannot keep food or drink down. The illness can unfold quickly, especially when a woman is repeatedly sent back into the community without an effective treatment plan.

That still means thousands of women each year face a condition severe enough to disrupt work, family life and routine antenatal care. The clinical picture is clear enough to require specific treatment pathways, not vague reassurance.

Where the postcode lottery begins

The access problem starts with how local NHS systems decide which drug comes first. Xonvea, the UK brand name for doxylamine succinate and pyridoxine hydrochloride, sits near the centre of that debate because some pathways treat it as a first-line option while others do not make it easy to obtain. In practice, that can mean one patient is offered it early, while another with the same symptoms is steered toward a different medicine or a longer wait for specialist review.

Ondansetron shows the same regional split. Some local NHS formularies place it later in the treatment pathway, and one Scottish guideline lists it as a fourth-line option. In some pathways, women with mild to moderate nausea and vomiting in pregnancy are managed in primary care, which makes sense only if the clinician knows when symptoms have crossed into hyperemesis gravidarum and when escalation is needed.

Awareness and referral become part of the barrier. If a GP follows a pathway that keeps treatment in primary care for too long, or if the local formulary reserves more effective medicine for later lines, a woman may spend days or weeks cycling through less helpful options. The result is a system in which access is shaped not just by diagnosis, but by the habits of the local pathway and the speed with which someone is referred on.

What the national guidance says

National guidance has tried to bring more consistency, but the rules still leave room for variation. NICE sets oral ondansetron for adults at 4 to 8 mg every 6 to 8 hours and covers use for hyperemesis gravidarum in secondary care in pregnancies of more than 20 weeks. That gives prescribers a clear dose framework, but it does not guarantee that every area uses the drug in the same place in the pathway.

The Royal College of Obstetricians and Gynaecologists updated its Green-top guideline on nausea and vomiting in pregnancy and hyperemesis gravidarum in February 2024. The updated guidance recommends NHS trusts change their pathways.

Why access matters beyond the prescription pad

If HG is not treated effectively, women are more likely to end up in hospital because they cannot maintain fluid intake, and repeated appointments can become a feature of care rather than an exception. Broader access to effective medication could reduce that cycle, easing pressure on emergency departments, maternity units and GPs who are left managing the fallout of delayed treatment.

A woman with the same diagnosis can receive a different drug, at a different stage, depending on the area she lives in and the clinician she sees. The route to treatment still changes from one NHS system to the next.